Claims

1. A peptidic compound having the formula (I):

R^1 - Z - R^2 (I)

wherein Z is a peptide moiety having the formula (II)

His-X2-X3-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-X14-X15-X16-X17-X18-Ala-X20-X21-Phe-Ile-Glu-Trp-Leu-Lys-X28-X29-Gly-Pro-Ser-Ser-Gly-X35-Pro-Pro-Pro-X39-X40 (II)

X2 represents an amino acid residue selected from Ser, D-Ser and Aib,
X3 represents an amino acid residue selected from Gln, His and α-amino-functionalized Gln, wherein Gln may be functionalized in that an H of the α-NH_2 group is substituted by (C_1-C_4)-alkyl,
X14 represents an amino acid residue selected from Lys, Orn, Dab and Dap,, wherein the -NH_2 side chain group is functionalized by -C(O)-R^5,
X15 represents an amino acid residue selected from Glu and Asp,
X16 represents an amino acid residue selected from Ser, Lys and Glu,
X17 represents an amino acid residue selected from Arg, Glu, Gln, Leuand Lys,
X18 represents an amino acid residue selected from Arg and Ala,
X20 represents an amino acid residue selected from Gln, Arg, Lys and Aib,
X21 represents an amino acid residue selected from Asp, Leu and Glu,
X28 represents an amino acid residue selected from Asn, Arg, Lys, Aib, Ser, Glu, Asp and Ala,
X29 represents an amino acid residue selected from Gly, Ala, D-Ala and Thr,
X35 represents an amino acid residue selected from Alaor Glu,
X39 is Ser or is absent,
X40 is either absent or represents Lys, wherein the -NH_2 side chain group can be functionalized by -C(O)-R^5 and

R^5 is a lipophilic moiety selected from an acyclic linear or branched (C_4-C_{30}) saturated or unsaturated hydrocarbon group, and/or a cyclic saturated, unsaturated or aromatic group, wherein the lipophilic moiety may be attached to the -NH_2 side

chain group by a linker selected from $(\beta\text{-Ala})_{1-4}$, $(\gamma\text{-Glu})_{1-4}$, $(\varepsilon\text{-Ahx})_{1-4}$, or $(GABA)_{1-4}$ in all stereoisomeric forms;

R^1 represents the N-terminal group of the peptidic compound and is selected from NH_2 and mono- or bisfunctionalized NH_2,
R^2 represents the C-terminal group of the peptidic compound and is selected from
(i) OH or functionalized OH and
(ii) NH_2 or mono- or bisfunctionalized NH_2,
or a salt or solvate thereof, and
wherein the compound is a dual GLP-1 and glucagon receptor agonist.

2. A compound of claim 1, wherein
X14 represents an amino acid residue selected from Lys, Orn, Dab and Dap, wherein the $-NH_2$ side chain group is functionalized by $-C(O)-R^5$,
X40 represents Lys, wherein the $-NH_2$ side chain group can be functionalized by $-C(O)-R^5$, and

$-C(O)-R^5$ is selected from
(S)-4-Carboxy-4-hexadecanoylamino-butyryl-, (S)-4-Carboxy-4-octadecanoylamino-butyryl-,4-Hexadecanoylamino-butyryl-, 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, 4-octadecanoylamino-butyryl-, 4-((Z)-octadec-9-enoylamino)-butyryl-, 6-[(4,4-Diphenyl-cyclohexyloxy)-hydroxy-phosphoryloxy]-hexanoyl-, Hexadecanoyl-, (S)-4-Carboxy-4-(15-carboxy-pentadecanoylamino)-butyryl-, (S)-4-Carboxy-4-{3-[3-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-propionylamino]-propionylamino}-butyryl, (S)-4-Carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, (S)-4-Carboxy-4-((9Z,12Z)-octadeca-9,12-dienoylamino)-butyryl-, (S)-4-Carboxy-4-[6-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-hexanoylamino]-butyryl, (S)-4-Carboxy-4-((2S,3R,4S,5R)-5-carboxy-2,3,4,5-tetrahydroxy-pentanoylamino)-butyryl, (S)-4-Carboxy-4-tetradecanoylamino-butyryl-, (S)-4-(11-Benzyloxycarbonyl-undecanoylamino)-4-carboxy-butyryl, (S)-4-Carboxy-4-[11-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxy-hexylcarbamoyl)-undecanoylamino]-butyryl-, (S)-4-Carboxy-4-((Z)-octadec-9-enoylamino)-butyryl-, (S)-4-Carboxy-4-(4-dodecyloxy-benzoylamino)-butyryl-, (S)-4-Carboxy-4-henicosanoylamino-butyryl-, (S)-4-Carboxy-4-

docosanoylamino-butyryl-, (S)-4-Carboxy-4-((Z)-nonadec-10-enoylamino)-butyryl-, (S)-4-Carboxy-4-(4-decyloxy-benzoylamino)-butyryl-, (S)-4-Carboxy-4-[(4'-octyloxy-biphenyl-4-carbonyl)-amino]-butyryl-, (S)-4-Carboxy-4-(12-phenyl-dodecanoylamino)-butyryl-, (S)-4-Carboxy-4-icosanoylamino-butyryl-, (S)-4-Carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (S)-4-Carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl-, 3-(3-Octadecanoylamino-propionylamino)-propionyl-, 3-(3-Hexadecanoylamino-propionylamino)-propionyl-, 3-Hexadecanoylamino-propionyl-, (S)-4-Carboxy-4-[(R)-4-((3R,5S,7R,8R,9R,10S,12S,13R,14R,17R)-3,7,12-trihydroxy-8,10,13-trimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-butyryl-, (S)-4-Carboxy-4-[(R)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-butyryl-, (S)-4-Carboxy-4-((9S,10R)-9,10,16-trihydroxy-hexadecanoylamino)-butyryl-, Tetradecanoyl-, 11-Carboxy-undecanoyl-, 11-Benzyloxycarbonyl-undecanoyl, (S)-4-Carboxy-4-((S)-4-carboxy-4-tetradecanoylamino-butyrylamino)-butyryl-, 6-[Hydroxy-(naphthalen-2-yloxy)-phosphoryloxy]-hexanoyl-, 6-[Hydroxy-(5-phenyl-pentyloxy)-phosphoryloxy]-hexanoyl-, 4-(Naphthalene-2-sulfonylamino)-4-oxo-butyryl-, 4-(Biphenyl-4-sulfonylamino)-4-oxo-butyryl-, (S)-4-Carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl-, (S)-4-Carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl, (S)-4-Carboxy-2-{(S)-4-carboxy-2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl, (S)-4-Carboxy-2-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl, (S)-4-Carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl, (S)-4-Carboxy-4-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl,(S)-4-Carboxy-2-{(S)-4-carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl, (S)-4-Carboxy-2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-butyryl, 2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-

ethoxy}-ethoxy)-acetyl-, 2-(2-{2-[(S)-4-Carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetyl, (S)-4-Carboxy-4-((S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)-butyrylamino]-butyrylamino}-butyrylamino)-butyryl, 2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(16-1H-tetrazol-5-yl-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl, 2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(16-carboxy-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl, (S)-4-Carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-butyrylamino}-butyryl, (S)-4-Carboxy-4-((S)-4-carboxy-4-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxy-phenoxy)-decanoylamino]-butyrylamino}-ethoxy)-ethoxy]-acetylamino}-ethoxy)-ethoxy]-acetylamino}-butyryl, (S)-4-Carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(7-carboxy-heptanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl, (S)-4-Carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(11-carboxy-undecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl, (S)-4-Carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(13-carboxy-tridecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl, (S)-4-Carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl, and (S)-4-Carboxy-4-{(S)-4-carboxy-4-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetylamino]-butyrylamino}-butyryl.

3. A compound of any one of claims 1 – 2,
wherein
R^1 is NH_2,
R^2 is NH_2 or
R^1 and R^2 are NH_2.

4. The compound of any one of claims 1 – 3
wherein
X14 is Lys, which is functionalized with a group $-C(O)R^5$, wherein R^5 is as described in any one of claims 1 -2.

5. The compound of any one of claims 1, 3, 4, wherein
X14 is Lys, which is functionalized with a group -C(O)R^5, wherein R^5 comprises a lipophilic moiety, an acyclic linear or branched (C_{12}-C_{22}) saturated hydrocarbon group attached directly to the -NH_2 side chain group or attached to the -NH_2 side chain group by a linker selected form the group of ß-Ala, γ-Glu, ß-Ala-ß-Ala and γ-Glu-γ-Glu in all stereoisomeric forms.

6. A compound of any one of claims 1 – 5, wherein
X2 represents an amino acid residue selected from D-Ser and Aib,
X3 represents Gln,
X14 represents an amino acid residue selected from Lys and Orn,, wherein the -NH_2 side chain group is functionalized by -C(O)-R^5,
X15 represents an amino acid residue selected from Glu and Asp,
X16 represents an amino acid residue selected from Ser and Glu,
X17 represents an amino acid residue selected from Arg, Glnand Lys,
X18 represents an amino acid residue selected from Arg and Ala,
X20 represents an amino acid residue selected from Gln, Arg, Lys and Aib,
X21 represents an amino acid residue selected from Asp, Leu and Glu,
X28 represents an amino acid residue selected from Asn, Arg, Lys, Aib, Ser and Ala,
X29 represents an amino acid residue selected from Gly, Ala, or Thr,
X35 represents Ala ,
X39 is Ser or is absent,
X40 is either absent or represents Lys, wherein the -NH_2 side chain group can be functionalized by -C(O)-R^5 and
-C(O)-R^5 is as defined in claim 1.

7. The compound of any one of claims 1 – 6, wherein
X20 represents an amino acid residue selected from Gln, Lys and Aib.

8. A compound of any one of claims 1 – 7, wherein
X2 represents an amino acid residue selected from D-Ser and Aib,
X3 represents Gln,
X14 represents Lys, wherein the -NH_2 side chain group is functionalized by one of the groups selected from 3-(3-octadecanoylamino-propionyl-amino)-propionyl-, 4-

hexadecanoylamino-butyryl-, 4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, 4-octadecanoylamino-butyryl-, 4-((Z)-octadec-9-enoylamino)-butyryl-, hexadecanoyl-, (S)-4-carboxy-4-((Z)-octadec-9-enoylamino)-butyryl-, (S)-4-carboxy-4-(4-dodecyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-henicosanoylamino-butyryl-, (S)-4-carboxy-4-docosanoylamino-butyryl-, (S)-4-carboxy-4-((Z)-nonadec-10-enoylamino)-butyryl-, (S)-4-carboxy-4-(4-decyloxy-benzoylamino)-butyryl-, (S)-4-carboxy-4-[(4'-octyloxy-biphenyl-4-carbonyl)-amino]-butyryl-, (S)-4-carboxy-4-(12-phenyl-dodecanoylamino)-butyryl-, (S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (S)-4-carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl-, (S)-4-carboxy-4-{3-[(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyl-tridecyl)-chroman-6-yloxycarbonyl]-propionylamino}-butyryl-, (S)-4-carboxy-4-((9Z,12Z)-octadeca-9,12-dienoylamino)-butyryl-, (S)-4-carboxy-4-octadecanoylamino-butyryl- and (S)-4-carboxy-4-hexadecanoylamino-butyryl-,

X15 represents Glu,

X16 represents Ser,

X17 represents an amino acid residue selected from Arg, Gln and Lys,

X18 represents Ala,

X20 represents Gln,

X21 represents Asp,

X28 represents Ala,

X29 represents Gly,

X35 represents Ala,

X39 is Ser

X40 is absent.

9. The compound of any one of claims 1 – 5, wherein

X2 represents Aib,

X3 represents Gln,

X14 represents Lys, wherein the -NH_2 side chain group is functionalized, particularly by (S)-4-Carboxy-4-hexadecanoylamino-butyryl- and (S)-4-Carboxy-4-octadecanoylamino-butyryl-;

X15 represents an amino acid residue selected from Asp and Glu,

X16 represents an amino acid residue selected from Ser and Glu,

X17 represents an amino acid residue selected from Gln and Lys,

X18 represents Ala,
X20 represents an amino acid residue selected from Gln and Lys,
X21 represents an amino acid residue selected from Asp and Leu,
X28 represents Ala,
X29 represents an amino acid residue selected from Gly and D-Ala,
X35 represents Ala,
X39 is Ser,
X40 is absent.

10. A compound of any one of claims 1 – 5, wherein
X2 represents D-Ser,
X3 represents Gln,
X14 represents Lys, wherein the -NH_2 side chain group is functionalized, particularly by (S)-4-carboxy-4-hexadecanoylamino-butyryl- or hexadecanoyl-;
X15 represents an amino acid residue selected from Glu and Asp,
X16 represents an amino acid residue selected from Ser and Glu,
X17 represents an amino acid residue selected from Arg, Glu, Lys and Aib,
X18 represents an amino acid residue selected from Arg, Lys and Ala,
X20 represents an amino acid residue selected from Gln, Lys and Aib,
X21 represents an amino acid residue selected from Asp and Leu,
X28 represents an amino acid residue selected from Ala and Asn,
X29 represents Gly,
X35 represents Ala,
X39 is Ser,
X40 is absent.

11. A compound of any one of claims 1 – 5, wherein
X2 represents an amino acid residue selected from Aib and D-Ser;
X3 represents an amino acid residue selected from Gln and His;
X14 represents Lys, wherein the -NH_2 side chain group is functionalized by one of the groups selected from (S)-4-Carboxy-4-hexadecanoylamino-butyryl-, (S)-4-Carboxy-4-octadecanoylamino-butyryl-, (S)-4-Carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)-butyryl-, (S)-4-Carboxy-4-((S)-4-carboxy-4-octadecanoylamino-butyrylamino)-butyryl-, 3-(3-Octadecanoylamino-propionyla-mino)-propionyl-, 3-(3-Hexadecanoylamino-propionyla-mino)-propionyl-, (S)-4-

Carboxy-4-henicosanoylamino-butyryl-, 4-Hexadecanoylamino-butyryl- and 4-octadecanoylamino-butyryl-,

X15 represents an amino acid residue selected from Asp and Glu;

X16 represents an amino acid residue selected from Ser and Glu;

X17 represents an amino acid residue selected from Arg, Gln, Lys, Aib and Leu;

X18 represents an amino acid residue selected from Arg and Ala;

X20 represents an amino acid residue selected from Gln, Aib and Lys;

X21 represents an amino acid residue selected from Asp, Glu and Lys;

X28 represents an amino acid residue selected from Asn, Ser, Aib, Ala and Arg;

X29 represents an amino acid residue selected from Gly, Thr, Ala and D-Ala;

X35 represents Ala;

X39 represents Ser and

X40 is absent.

12. A compound of any one of claims 1 - 7, wherein

the functionalized Lys in position 14 is functionalized at its ε-amino group with -C(O)-R^5, and-C(O)-R^5 is (S)-4-carboxy-4-hexadecanoyl-amino-butyryl, (S)-4-carboxy-4-octadecanoylamino-butyryl, hexadecanoyl or octadecanoyl.

13. A compound of claim 12, wherein

X2 represents an amino acid residue selected from Aib and D-Ser;

X3 represents Gln;

X14 represents Lys, wherein the -NH_2 side chain group is functionalized by one of the groups selected from (S)-4-carboxy-4-hexadecanoyl-amino-butyryl, (S)-4-carboxy-4-octadecanoylamino-butyryl, hexadecanoyl and octadecanoyl;

X15 represents Glu;

X16 represents Ser;

X17 represents an amino acid residue selected from Arg, Gln and Lys;

X18 represents Ala;

X20 represents Gln;

X21 represents Asp;

X28 represents Ala;

X29 represents Gly;

X35 represents Ala;

X39 represents Ser and

X40 is absent.

14. The compound of any one of claims 1 – 5, wherein
X2 represents Aib,
X3 represents Gln,
X14 represents Lys, wherein the -NH_2 side chain group is functionalized, particularly by (S)-4-Carboxy-4-henicosanoylamino-butyryl- and (S)-4-Carboxy-4-octadecanoylamino-butyryl-;
X15 represents Asp,
X16 represents an amino acid residue selected from Lys and Glu,
X17 represents an amino acid residue selected from Arg and Glu,
X18 represents an amino acid residue selected from Ala and Arg,
X20 represents an amino acid residue selected from Gln and Lys,
X21 represents an amino acid residue selected from Asp and Leu,
X28 represents Ala,
X29 represents an amino acid residue selected from Gly and D-Ala,
X35 represents Ala,
X39 is Ser,
X40 is absent.

15. The compound of any one of claims 1-14, selected from the compounds of SEQ ID NO. 4-10, 16-22, 24-81, 84-129, 133-164, 166-181 or a salt or solvate thereof.

16. The compound of any one of claims 1-14, selected from the compounds of SEQ ID NO. 4-10, 16-22, 24-81, 84-129, 133-164, 166-181, 196-205, 207-223, 226-229 or a salt or solvate thereof.

17. The compound of claim 1, wherein the compound is represented by SEQ ID NO.: 24, or a salt or solvate thereof.

18. The compound of claim 1, wherein the compound is represented by SEQ ID NO.: 35, or a salt or solvate thereof.

19. The compound of claim 1, wherein the compound is represented by SEQ ID NO.: 36, or a salt or solvate thereof.

20. The compound of claim 1, wherein the compound is represented by SEQ ID NO.: 44, or a salt or solvate thereof.

21. The compound of claim 1, wherein the compound is represented by SEQ ID NO.: 97, or a salt or solvate thereof.

22. Compound according to any one of claims 1-21, which has a high solubility at acidic pH values, e.g. at pH 4.5 at 25°C, and/or at physiological pH values, e.g., at pH 7.4 at 25ºC, wherein the solubility at said pH value and/or pH values is particularly at least 0.5 mg/ml, or at least 1.0 mg/ml.

23. The compound of any one of claims 1-22 for use in medicine, particularly in human medicine.

24. The compound for use according to claim 23 which is present as an active agent in a pharmaceutical composition together with at least one pharmaceutically acceptable carrier.

25. The compound for use according to claim 23 or 24 together with at least one additional therapeutically active agent, wherein the additional therapeutically active agent is selected from the series of Insulin and Insulin derivatives, GLP-1, GLP-1 analogues and GLP-1 receptor agonists, polymer bound GLP-1 and GLP-1 analogues, dual GLP1/GIP agonists, PYY3-36 or analogues thereof, pancreatic polypeptide or analogues thereof, Glucagon receptor agonists, GIP receptor agonists or antagonists, ghrelin antagonists or inverse agonists, Xenin and analogues thereof, DDP-IV inhibitors, SGLT2 inhibitors, dual SGLT2 / SGLT1 inhibitors, Biguanides Thiazolidinediones, dual PPAR agonists, Sulfonylureas, Meglitinides, alpha-glucosidase inhibitors, Amylin and Amylin analogues, GPR119 agonists, GPR40 agonists, GPR120 agonists, GPR142 agonists, systemic or low-absorbable TGR5 agonists, Cycloset, inhibitors of 11-beta-HSD, activators of glucokinase, inhibitors of DGAT, inhibitors of protein tyrosinephosphatase 1, inhibitors of glucose-6-phosphatase, inhibitors of fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, inhibitors of phosphoenol pyruvate carboxykinase, inhibitors of glycogen synthase kinase, inhibitors of pyruvate dehydrogenase kinase, alpha2-antagonists, CCR-2 antagonists, modulators of

glucose transporter-4, Somatostatin receptor 3 agonists, HMG-CoA-reductase inhibitors, fibrates, nicotinic acid and the derivatives thereof, nicotinic acid receptor 1 agonists, PPAR-alpha, gamma or alpha/gamma) agonists or modulators, PPAR-delta agonists, ACAT inhibitors, cholesterol absorption inhibitors, bile acid-binding substances, IBAT inhibitors, MTP inhibitors, modulators of PCSK9, LDL receptor up-regulators by liver selective thyroid hormone receptor ß agonists, HDL-raising compounds, lipid metabolism modulators, PLA2 inhibitors , ApoA-I enhancers, thyroid hormone receptor agonists, cholesterol synthesis inhibitors, omega-3 fatty acids and derivatives thereof, active substances for the treatment of obesity, such as Sibutramine, Tesofensine, Orlistat, CB-1receptor antagonists, MCH-1 antagonists, MC4 receptor agonists and partial agonists, NPY5 or NPY2 antagonists, NPY4 agonists, beta-3-agonists, leptin or leptin mimetics, agonists of the 5HT2c receptor, or the combinations of bupropione/naltrexone (CONTRAVE), bupropione/zonisamide (EMPATIC), bupropione/phentermine or pramlintide/metreleptin, QNEXA (Phentermine+ topiramate), lipase inhibitors, angiogenesis inhibitors, H3 antagonists, AgRP inhibitors, triple monoamine uptake inhibitors (norepinephrine and acetylcholine), MetAP2 inhibitors, nasal formulation of the calcium channel blocker diltiazem, antisense against production of fibroblast growth factor receptor 4, prohibitin targeting peptide-1, drugs for influencing high blood pressure, chronic heart failure or atherosclerosis, such as angiotensin II receptor antagonists, ACE inhibitors, ECE inhibitors, diuretics, beta-blockers, calcium antagonists, centrally acting hypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors.

26. The compound for use according to claim 23 or 24 together with at least one additional therapeutically active agent, wherein the additional therapeutically active agent particularly is a GLP-1 compound and/or an insulinic compound and/or a gastrointestinal peptide.

27. The compound for use according to claim 23 or 24 together with at least one additional therapeutically active agent, wherein the additional therapeutically active agent particularly is insulin or an insulin derivative.

28. The compound for use according to claim 23 or 24, wherein the pharmaceutical composition is for parenteral administration, preferably in a single dose injectable form, particularly in the form of a pen.

29. The compound for use according to any one of claims 23 – 28 for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, metabolic syndrome and neurodegenerative disorders, particularly for delaying or preventing disease progression in type 2 diabetes, treating metabolic syndrome, treating obesity or preventing overweight, for decreasing food intake, increase energy expenditure, reducing body weight, delaying the progression from impaired glucose tolerance (IGT) to type 2 diabetes; delaying the progression from type 2 diabetes to insulin-requiring diabetes; regulating appetite; inducing satiety; preventing weight regain after successful weight loss; treating a disease or state related to overweight or obesity; treating bulimia; treating binge eating; treating atherosclerosis, hypertension, IGT, dyslipidemia, coronary heart disease, hepatic steatosis, treatment of beta-blocker poisoning, use for inhibition of the motility of the gastro-intestinal tract, useful in connection with investigations of the gastro-intestinal tract using techniques such as X-ray, CT- and NMR-scanning.

30. The compound for use according to any one of claims 23 – 29 for the treatment or prevention of hyperglycemia, type 2 diabetes, obesity and metabolic syndrome or reducing body weight.

31. The compound for use according to any one of claims 23 – 29 for simultaneous treatment of obesity and diabetes.